The FDA's approval in tricuspid regurgitation adds the clip-based Pascal Precision alongside Edwards’ Evoque implant for replacing the valve.

Clinicians have been using this device to perform M-TEER for years. After this latest announcement, it is now officially ...

The PASCAL Precision device is indicated to treat individuals with symptomatic severe tricuspid regurgitation.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Edwards Lifesciences has received approval for its Pascal system for tricuspid valve disease, expanding treatment options ...

Transcatheter edge-to-edge repair (M-TEER) for mitral regurgitation (MR).MitraClip is a representative device, but in recent ...

Edwards said FDA approval of Pascal Ace with capture clarity simplifies mitral TEER procedures for clinicians. Edwards Lifesciences reported that FDA has approved its Pascal Precision system for ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

Newswise — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed two novel minimally invasive cardiac procedures for the first time in the health ...

Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL ...

Edwards’ approval should “strengthen the company’s position in the large and underpenetrated transcatheter tricuspid market,” ...